Topical vidarabine or 5-fluorouracil treatment against persistent HPV in genital (pre)cancerous lesions.
In the present study, effectiveness of topical vidarabine or subsequent 5-fluorouracil (5-FU) administration was examined against persistent genital human papillomavirus (HPV) infection after local surgery. Thirty patients underwent local eradication treatment of uterine cervical intra-epithelial neoplasia (CIN) and stage Ia1 uterine cervical cancers. HPV typing was performed by PCR-RFLP analysis. HPV infection was detected pre-operatively in 29 of 30 patients. Of these, HPV was still present in the 20 patients within two months after the therapy. Topical administration of vidarabine or subsequent 5-FU once a week for four weeks was performed to the post-operative persistent HPV-positive cases. HPV infection was abolished in 1 of 10 (10%) with topical vidarabine, and in 2 of 4 vidarabine-resistant cases (50%) with topical 5-FU. Topical vidarabine or 5-FU treatment is beneficial for HPV-positive cases after local surgical excision.
Niwa
Kenji
K
Department of Obstetrics and Gynecology, Gifu University School of Medicine, Gifu-city 500-8705, Japan. kniwa@cc.gifu-u.ac.jp
Tagami
Keiko
K
Lian
Zenglin
Z
Gao
Jingchun
J
Mori
Hideki
H
Tamaya
Teruhiko
T
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D027383:Papillomaviridae / Q000378:metabolism*; D030361:Papillomavirus Infections / Q000188:drug therapy*; D012150:Polymorphism, Restriction Fragment Length; D011230:Precancerous Conditions / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy; D014740:Vidarabine / Q000008:administration & dosage* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D000998:Antiviral Agents; D014740:Vidarabine; D005472:Fluorouracil